Abstract
Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Psychopharmacology |
Vol/bind | 219 |
Udgave nummer | 3 |
Sider (fra-til) | 687-98 |
Antal sider | 12 |
ISSN | 0033-3158 |
DOI | |
Status | Udgivet - 2012 |